Palleon Pharmaceuticals Presents GLIMMER-01 Trial Results of E-602 and Cemiplimab at SITC Annual Meeting

Palleon Pharmaceuticals, a clinical-stage company leading innovation in glyco-immunology for autoimmune diseases and cancer, today announced results from the Phase 1/2 GLIMMER-01 trial of E-602. This first-in-class human sialidase enzyme…

Read MorePalleon Pharmaceuticals Presents GLIMMER-01 Trial Results of E-602 and Cemiplimab at SITC Annual Meeting